Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.39 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.39 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.39 |
| ▸ | ITGA8 | P53708 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.39 |
| ▸ | CTSA | P10619 | 3/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7558907 | 0.99 | F10 (0.41) | F10PRSS1ITGB3ITGB1ITGAV | |
| Hydrochloric Acid SCHEMBL6556783 | 0.89 | ITGB3 (0.41) | F10PRSS1ITGB3F2ITGA2B | |
| SCHEMBL6350317 | 0.89 | ACACB (0.41) | F10PRSS1F2ACACB | |
| Hydrochloric Acid SCHEMBL6350375 | 0.88 | ACACB (0.41) | F10PRSS1F2ACACB | |
| SCHEMBL6554435 | 0.86 | F10 (0.42) | F10PRSS1ITGB3F2ITGA2B | |
| SCHEMBL7558652 | 0.85 | F10 (0.49) | F10PRSS1ITGB3F2ITGA2B | |
| Hydrochloric Acid SCHEMBL7558537 | 0.85 | F10 (0.41) | F10PRSS1ITGB3F2ITGA2B | |
| Hydrochloric Acid SCHEMBL6554532 | 0.85 | F10 (0.48) | F10PRSS1ITGB3F2ITGA2B | |
| SCHEMBL6555829 | 0.85 | ACACB (0.42) | CTSAACACB | |
| SCHEMBL6340740 | 0.83 | F10 (0.39) | F10PRSS1F2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | claimed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | F10 35/4885PRSS1 776/4885ITGB3 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.